Navigation Links
University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding
Date:10/15/2008

WASHINGTON, Oct. 15 /PRNewswire/ - A popular drug used to prevent blood clotting during the treatment of severe heart attacks does not improve outcomes for patients undergoing a life-saving surgical procedure. Further, the drug - known generically as eptifibatide (pronounced ep-ti-fy-bah-tide) - also increases the risk of bleeding. The results follow a ground-breaking clinical trial conducted at the University of Ottawa Heart Institute (UOHI) which sought to determine the efficacy of a drug that is widely used but for which little clinical evidence was available to indicate a positive impact on treatment.

The three-year trial, called ASSIST, was designed to test the safety and efficacy of eptifibatide in serious heart attack patients who underwent an emergency angioplasty - called primary PCI - to open blood and oxygen flow to the heart. The study involved a total of 400 patients diagnosed with ST-Segment Elevation Myocardial Infarction (STEMI) at UOHI; 200 undergoing primary PCI using eptifibatide, and 200 who did not. The Heart Institute's trial results showed that using eptifibatide did not significantly improve patient outcomes. In fact, the study found that using the drug increased the risk of bleeding.

"We believe there is no supporting evidence to be incorporating this drug therapy for the treatment of acute STEMI patients, said Dr. Michel Le May, Director, Coronary Care Unit

Research Group, UOHI. "In fact, there is increased risk associated with its use. As a result, we expect this study will reshape our current clinical practice of medicine in managing the treatment and care of heart attack patients."

Dr. Le May presented the findings of the ASSIST trial today in Washington, D.C. at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) Symposium, where interventional cardiologists from around the world gather to discuss innovative techniques and therapies in cardiovascular medicine.

About UOHI

The University of Ottawa Heart Institute is Canada's largest and foremost cardiovascular health centre dedicated to understanding, treating and preventing heart disease. We deliver high-tech care with a personal touch, shape the way cardiovascular medicine is practiced, and revolutionize cardiac treatment and understanding. We build knowledge through research and translate discoveries into advanced care. We serve the local, national and international community, and are pioneering a new era in heart health. For more information, visit http://www.ottawaheart.ca

/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on

the CNW Photo Network and archived at http://photos.newswire.ca.

Additional archived images are also available on the CNW Photo Archive

website at http://photos.newswire.ca. Images are free to accredited

members of the media/


'/>"/>
SOURCE Ottawa Heart Institute, University of Ottawa
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford University Rises to Top of 2008 Trojan(R) Sexual Health Report Card
2. LodgeNet Healthcare Signs New Agreement with NorthShore University HealthSystem
3. The Lanier Law Firm Announces Wrongful Death Lawsuit Against Rice University, Former Coach, NCAA, Others in Students Sickle-Cell Death
4. AARP: Cornell University Tops 2008 List of Best Employers for Workers Over 50
5. Staten Island University Hospital to Pay the U.S. $74 Million to Settle Claims of Defrauding Federal Health Care Programs
6. University of Washington School of Social Work and Partners for Our Children Awarded Top National Recognition
7. Harvard University recipient of Global Health Nutrition grant
8. Mayo Clinic, McMaster University Research Review Shows Internet-based Instruction Effective for Teaching Health Care Professionals
9. Delft University of Technology patent for manufacturing radio isotopes
10. University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services
11. PAs Smoking Ban Should Filter Into Homes and Cars Too, According to Temple University Expert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, Carol Bryan ... resulted in severe facial disfiguration. After four frightening years of isolation and emotional ... Medical Center, who removed the substances in a partial facial transplant through eight ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this ... The Tranquility privacy panel system was designed to deliver the ideal blend of ... noise and provide the visual privacy required to maintain concentration levels and increase ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Sam ... planning assistance to commercial and residential clients in the California Bay Area, is launching ... heart health in the region. , Heart disease is the primary killer of adult ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a ... sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
Breaking Medicine Technology: